The Impact of the COVID-19 Pandemic on Colorectal Cancer Patients in a Tertiary Center in Romania. Single Center Retrospective Study

Botond István Kiss1, Tatiana Daniela Sala1*, Árpád Török1, Márton István Dénes1, Cristian Oliviu Borz1, Gabriel Alexandru Popescu1, Tivadar Bara Jr1, Mircea Gabriel Muresan1, Ruxandra Darie1, Valentin Daniealopol1, Georgiana Alexandra Scurtu1, Tamás Székely1, Andrea Gábor-Kelemen1, Zsolt Fülöp1, Kálmán Gabriel Sárdi1, Szlárd Leó Kiss1, Radu Mircea Neagoe1

12nd Department of Surgery, Emergency Mures County Clinical Hospital, University of Medicine, Pharmacy, Science and Technology “George Emil Palade” Târgu Mureș, Romania
2nd Department of Surgery, University of Medicine, Pharmacy, Science and Technology “George Emil Palade” Târgu Mureș, Romania

*Corresponding author:
Sala Tatiana Daniela, MD
2nd Department of Surgery
Emergency Mures County Clinical Hospital, University of Medicine, Pharmacy, Science and Technology “George Emil Palade” Tg Mures, Romania, Strada Pictor N Grigorescu Nr.15/11, Târgu Mures
E-mail: salatatiana@yahoo.com

Rezumat

Impactul pandemiei COVID-19 asupra pacienților cu cancer colorectal într-un centru terțiar din România. Studiu retrospectiv, experiența unui singur centru

Introducere: Noul coronavirus, SARS-COV-2, a fost raportat pentru prima dată în Wuhan, China, la sfârșitul anului 2019. Pentru a reduce răspândirea virusului, au fost implementate măsuri de siguranță, care, din multiple motive, au condus la întârzieri în tratamentul cancerului colorectal. În prezent nu se știe încă, cum a influențat pandemia eficacitatea și rezultatele tratamentului cancerului colorectal în România.

Material și metodă: Am evaluat datele demografice, clinice, statusurile intraoperatorii și datele morfopatologice ale pacienților diagnosticăți cu cancer colorectal în clinica noastră, 302 în total, în perioada 15.03.2019 - 14.03.2021. Pacienții din 2019 au fost încadrați în grupul de control, iar cei tratați în pandemie, în grupul de studiu.

Rezultate: Am observat o scădere cu 12% a spitalizărilor pentru tratamentul cancerului colorectal în perioada pandemiei, în primele șase luni această scădere a fost de peste 38%. Rata internărilor de urgență, procedurilor chirurgicale cu colo/ileo-stomie, rezecțiilor palliative și a metastazelor clinice a fost mai mare în grupul pandemic. S-a constatat invazia loco-regională mai
Introduction

The first cases of COVID-19 infectious disease, caused by the novel coronavirus SARS-COV-2, was reported in Wuhan, Hubei Province, China in the end of the year 2019 (1). Due to the high contagiousness and rapid spread of the disease around the globe, the WHO declared the COVID-19 outbreak a pandemic in 11th March of 2020 (2). Due to the fact that many key questions regarding this novel strain of the coronavirus family were unanswered, vaccines were unavailable and the pressure on the ICU wards were mounting, guidelines were issued to help prevent the spread of the disease (3). In many countries severe restrictions were implemented, the non-emergency admissions in hospitals suddenly declined (4,5,6). The screening rate of the population plummeted resulting in huge delays in diagnosis and surgery resulting in fewer cancer operations in this period (5,7,8). In the UK, it is estimated that colon cancers deaths will have one of the biggest rise, between 15.3-16.6%, after 5 years form the diagnosis (8). On the 16th of March, the
Romanian government introduced harsh restrictions (social distancing, curfew, mandatory face covering) in order to curb rising infection rate and to help lower the mounting pressure on hospitals. Hospital bed capacity was limited, in many cases elective operations were halted completely, only emergency admissions were allowed (9,10).

Our objective was to study and quantify the effects of the COVID-19 restrictions in Romania, by analyzing the admission rate of colorectal patients in our facility. Our goal was to assess the clinical and pathological characteristics of our patients, whose treatment suffered major disruptions and delays because of the pandemic.

Material and Methods

In our single center retrospective cohort study, we included data of 302 patients admitted in our Clinic for colorectal carcinoma in a period of two years between 15.03.2019 and 14.03.2021. To compare surgical care during pandemic times with pre-pandemic times; we formed a study group, patients admitted while the COVID-19 restrictions were in effect, between 15.03.2020 and 14.03.2021; and a control group, patients hospitalized between 15.03.2019 and 14.03.2020.

We collected our data from H3 Healthcare Concept System, which is the medical data-base of our clinic, and from histopathological reports. For this study we created a database using the Microsoft Excel spreadsheet program and analyzed our data with IBM SPSS Statistics program.

Our criteria of exclusion were: patient younger than 18 years old, benign tumor diagnosis after histopathologic examination, positive COVID-19 RT-PCR test for elective patients (they were discharged for home quarantine immediately). In our inclusion criteria we used the ICD-10 (10th Edition of International Classification of Diseases) diagnosis system and selected our patients after the following diagnosis codes: C18, C19, C20. In case of D37.4, D37.5, D37.9 diagnoses we selected the case if the histopathological examinations described a malignant tumor.

We assessed demographic, clinical, operative, postoperative and histopathological data to create our database. We additionally calculated the cancer stage of each case according to the AJCC 8th edition and DUKES classification.

Statistical Analysis

Quantitative variables were determined in mean ± standard deviation, whereas qualitative variables were expressed in integers and percentages. For identifying outliers we used the Grubbs test. Every variable was subjected to a normality test. Our variables were unpaired ones. For variables with Gaussian distribution we used student T test and for nonparametric ones we applied Mann-Whitney tests. For categorical variables Fisher’s exact test and Chi squared test were applied. The level of significance was determined at p=0.05. Confidence interval of 95% was used.

Results

We found no significant differences between the study group (pandemic era) and the control group (prepandemic era) in demographic data (Table I). The two studied population had similar average age (p=0.670), similar gender ratio (p=0.139). We assessed our patients addresses and found no significant differences between the rural and urban patients. The proportion of rural patients did not drop since the start of the pandemic, not even in emergency cases. Patients during and before the pandemic had similar tumor localization (p=0.678, Fig. 1) and had similar procedure types (p=0.787, Fig. 2) for these tumors. We had two similar, comparable colorectal cancer groups.

Our data showed a 12% decrease in hospital admissions for colorectal cancer diagnosis in the first year of COVID-19 restrictions in comparison with the year before that. In the first six months the patient influx decrease was more substantial (~38.4%) (Fig. 3). A change in
some clinical variables was reported during the pandemic ($T_{p,dy,\gamma}$). Between the two groups, there were no significant differences in number of patients, who received neoadjuvant therapy prior to the surgical intervention ($p=0.518$). Similar results were acquired if only the rectum and rectosigmoid carcinomas were taken into account ($p=0.270$). The average hospitalization time in the pandemic group was similar to the year before the national lockdown ($p=0.526$). There were no changes reported in ICU stay between the two main groups ($p=0.141$). The in-

Table 1. Demographical and clinical characteristics of colorectal patients

| Study Group | Control Group | p value |
|-------------|---------------|---------|
| n = 142 (%) | n = 160 (%)   |         |
| Age         |               |         |
| 67.08       | 67.66         | 0.670   |
| Standard Deviation | 10.90 | 12.25 |
| Sex         |               | 0.139   |
| Female      | 55 (38.7)     |         |
| Male        | 87 (61.3)     |         |
| Adress      |               | 0.839   |
| Urban       | 70 (49.3)     |         |
| Rural       | 72 (50.7)     |         |
| Adress – emergency presentation | | |
| Urban       | 31 (53.4)     |         |
| Rural       | 27 (46.6)     |         |
| Presentation|               | 0.424   |
| Emergency   | 58 (40.8)     |         |
| Chronic     | 84 (59.2)     |         |
| Age distribution of patients | | |
| <25         | 0 (0)         | 1 (0.6) | 1.000 |
| 25-50       | 12 (8.5)      | 18 (11.3)| 0.417 |
| 51-75       | 96 (67.6)     | 91 (56.9)| 0.055 |
| >75         | 34 (23.9)     | 50 (31.3)| 0.157 |
| Intervention type | | |
| Palliative  | 74 (52.9)     | 58 (37.7)| 0.009 |
| Curative    | 66 (47.1)     | 96 (62.3)| 0.009 |
| Metastases  |               | 0.002   |
| Yes         | 38 (26.8)     | 20 (12.5)|         |
| No          | 104 (73.2)    | 140 (87.5)|         |
| Stoma       |               | 0.035   |
| Colo/ileostomy | 62 (43.7) | 51 (31.9)|         |
| Without     | 80 (56.3)     | 109 (68.1)|         |
| Approach    |               | 0.430   |
| Classic     | 133 (93.7)    | 146 (91.3)|         |
| Laparoscopic| 9 (6.3)       | 14 (8.8) |         |
| Hospital mortality | | |
| Yes         | 16 (11.3)     | 12 (7.5) | 0.259 |
| No          | 125 (88.7)    | 147 (92.5)| 0.259 |
| Anastomosis |               | 0.625   |
| Yes         | 67 (47.2)     | 80 (50)  |         |
| No          | 75 (52.8)     | 80 (50)  |         |
| Stappled    | 34 (23.9)     | 42 (25.5) |         |
| Hand sewn   | 33 (49.3)     | 38 (47.5) |         |
| Neoadjuvant therapy | | |
| Yes         | 25 (17.6)     | 23 (14.8) | 0.518 |
| No          | 117 (82.4)    | 132 (85.2)| 0.518 |
| Length of hospital stay | | |
| Mean        | 11.00         | 10.30    | 0.526 |
| Standard deviation | 7.659 | 5.066 |
| Length of ICU stay | | |
| Mean        | 3.792         | 2.962    | 0.141 |
| Standard deviation | 3.922 | 2.676 |

ICU – intensive care unit
Figure 1.  Tumor localization

Figure 2.  Type of procedures preformed for colorectal patients

Figure 3.  Monthly admission rate of colorectal cancer patients
SG – study (pandemic) group, CG – control group
hospital mortality was alike between the two groups (p=0.259). Emergency presentations were significantly more common in the study group (p=0.014). Cases were considered acute and operated in emergency setting if the patient presented massive hemorrhage, bowel obstruction due to stenotizing tumor, acute abdomen caused by perforated bowel with localized or generalized peritonitis. In the pandemic group more patients had procedures that ended with permanent or temporary stoma formation (p=0.035). Hartmann’s procedures, colostomies without resection, abdominoperineal rectum resections were the interventions which resulted in colo/ileostomy. After the implementation of COVID-19 restrictions the proportion of palliative surgical care has increased according to our first year results (p=0.009). We had a lower rate of curative resections in the study group in comparison with the control group (p=0.009). We observed more clinical metastasis during the procedures, in cases operated after March of 2020 (p=0.002), mainly hepatic metastases. We did not find a statistically significant difference between the two groups regarding postoperative complications that needed reintervention of inpatients. Similar ratio of surgical approach was seen, same laparoscopy/laparotomy ratio. (p=0.430). We did not detect any differences in use of mechanical stapler for bowel anastomosis, same hand sewn/stapled anastomosis ratio (p=0.823). Same results when the analysis was narrowed to elective (p=0.765) and emergency operations (p=0.264).

Histopathological results shed light on some major differences between the study and the control group (Table 2). Patients from the study group had a more advanced loco-regional tumor spread (p=0.026). We saw the same tendency in case of the vascular and perineural invasion. From the total of 200 cases where perineural invasion was measurable, in the study (pandemic) group 40 (43%) and in the control group (prepandemic) 30 (28%) had positive perineural invasion in their histopathological report (p=0.027). Similarly, the patients from the study group had more chance of developing a vascular invasion. Whilst in the control group only 30.2% of the patients had vascular invasion, this was more frequent in the study group with 47.5% of the cases (p=0.011). We did not observe important differences though, in lymphatic invasion between the groups (p=0.411). In cases where the tumoral resection was possible the resection margins of the specimens where examined. To achieve an R0 resection it is key that the edges of the resected specimens are completely clear of cancerous cells (negative resection margin). In our study, amongst the patients who were treated while the pandemic restrictions were in place the share of the positive resection margin on histopathological reports were significantly higher (p=0.032). We measured the differences in tumor progression of cases by grouping them into stages. For colorectal cancer staging we used, the AJCC’s 8th Edition, and the now less frequently utilized Dukes classification. According to these classifications, more advanced tumor advancement was observed in the pandemic group (AJCC p=0.003, DUKES p<0.001). According to the AJCC classification, we found in the study group 34.6% of the cases with stage IV tumor (only 17.1% in the control group). The number of resected lymph nodes were higher in the pandemic (p<0.001). Though, the average lymph node resection number is highly influenced by the type of procedure. Although we did not observe any statistical differences between the two groups in metastatic lymph node count (p=0.257) and lymph node ratio (LNR) (p=0.525), it is important to state that in the pandemic group we had on average more metastatic lymph nodes and the also the LNR was higher.

**Discussion**

The global pandemic brought a lot of uncertainties into the colorectal cancer care. In the beginning of the pandemic several restrictions were implemented in cancer care which led to a major disruption in the colorectal cancer care (11). A general fear of the rapidly spreading virus discouraged the
patients of contacting their general practitioner while experiencing symptoms (12). Delays of surgical treatment leads to a sharp increase in mortality and morbidity (6). Worldwide surgical wards saw a serious decrease in colorectal cancer operations (13,14). Colorectal cancer screening programs suffered major setbacks, thus early cancer diagnosis declines (15). According to M. Abdellatif et al, 57.4% of their patients had a delay in the treatment plan

| Pathological data of the colorectal patients |
|---------------------------------------------|
|                                  | Study group | Control Group |         |          |
|                                  | n (%)       | n (%)         | p value |
| Local invasion (T)               |             |               | 0.026   |
| Mean                            | 3.75        | 3.41          |         |
| SD                              | 0.87        | 0.90          |         |
| T1=1                            | 2 (1.9)     | 2 (1.8)       |         |
| T2=2                            | 4 (3.8)     | 12 (10.6)     |         |
| T3=3                            | 32 (30.2)   | 50 (44.2)     |         |
| T4a=4                           | 48 (45.3)   | 35 (31)       |         |
| T4b=5                           | 20 (18.9)   | 14 (12.4)     |         |
| Lymphatic invasion (L)          |             |               | 0.411   |
| Yes                             | 64 (64.6)   | 62 (59.0)     |         |
| No                              | 35 (35.4)   | 43 (41.0)     |         |
| Vascular invasion (V)           |             |               | 0.411   |
| No                              | 52 (52.5)   | 74 (69.8)     |         |
| Yes                             | 47 (47.5)   | 32 (30.2)     |         |
| Perineural invasion (Pn)        |             |               | 0.027   |
| Yes                             | 40 (43.0)   | 30 (28.0)     |         |
| No                              | 53 (57.0)   | 77 (72.0)     |         |
| Resection margins               |             |               | 0.027   |
| Positive                        | 20 (19.8)   | 10 (9.3)      |         |
| Negative                        | 81 (80.2)   | 97 (90.7)     |         |
| AJCC Stadialization             |             |               | 0.003   |
| Mean                            | 5.64        | 4.53          |         |
| SD                              | 2.385       | 2.381         |         |
| I = 1                           | 4 (3.8)     | 9 (8.1)       |         |
| IIa=2                           | 12 (11.9)   | 24 (21.6)     |         |
| IIb=3                           | 16 (15.4)   | 17 (15.3)     |         |
| Ilc=4                           | 2 (1.9)     | 5 (4.5)       |         |
| Ilc=5                           | 0 (0.0)     | 2 (1.8)       |         |
| Ilb=6                           | 23 (22.1)   | 32 (28.8)     |         |
| Ilc=7                           | 11 (10.6)   | 3 (2.7)       |         |
| N=8                             | 36 (34.6)   | 19 (17.1)     |         |
| DUKEs stadalization             |             |               | <0.0001 |
| Mean                            | 4.37        | 3.59          |         |
| SD                              | 1.54        | 1.43          |         |
| A = 1                           | 2 (1.9)     | 2 (1.8)       |         |
| B1=2                            | 14 (13.6)   | 31 (27.9)     |         |
| B2=3                            | 19 (18.4)   | 22 (19.8)     |         |
| C1=4                            | 13 (12.6)   | 31 (27.9)     |         |
| C2=5                            | 19 (18.4)   | 6 (5.4)       |         |
| D=6                             | 36 (35.0)   | 19 (17.1)     |         |
| Lymph node yield                |             |               | <0.0001 |
| Mean                            | 23.26       | 14.93         |         |
| Standard deviation              | 13.984      | 8.231         |         |
| Metastatic lymph node (+L)      |             |               | 0.257   |
| Mean                            | 2.20        | 1.61          |         |
| Standard deviation              | 3.722       | 3.751         |         |
| LNR                             | 0.116       | 0.998         | 0.525   |
| Standard deviation              | 0.195       | 0.181         |         |

$LNR$ – lymph node ratio, $SD$ – standard deviation
because of the pandemic (16). Giulio A Santoro et al reports that almost half of cases (48.9%) had a change in the original treatment plan and 26.3% of elective patients had emergency operation while waiting for appointment (5).

As in our case, many hospitals reported a more severe decrease in operations in the first half of the pandemic year. As the total number of admissions plummeted, the proportion of emergency operations for complicated colorectal cancer was on the rise (11). Some authors recommended stoma-formatting procedures over anastomosis to reduce the duration of hospital stay and the incidence of anastomotic leakage. The combination of anastomotic leakage and SARS-COV-2 infection results in soaring mortality rates (17). Our data shows also a growth in stoma operations, but probably the reason is that, more tumors were not resectable, and more patients were operated under emergency conditions, when preoperative preparation of the bowel is not possible for primary anastomosis.

Minimal invasive procedures suffered a decline in the pandemic times. In our clinic the laparoscopic approach is not widespread yet, and only a few very selected cases are operated this way. If it had not been for the low number of laparoscopic colorectal resections, most likely the decrease in our facility would be significant. Stappled anastomosis rates has seen a growth in pandemic times which reflects the efforts of minimizing the length of hospitalization (17). Our trends of using stappled anastomosis is seriously restricted by the lack of resources our institution has. International studies matches our data: more palliative procedures were performed in the COVID-19 pandemic than before, with parallel decrease of curative resections. Some authors also concluded that the resection of adjacent organs was more common in that period (13). We categorized as palliative operations the following: colostomy or ileostomy without resection, laparotomy plus biopsy, palliative resection, cytoreductive surgery. The demographic and clinical characteristics of the patients, included in our study, were typical of those observed in colorectal cancer patients treated at our institution.

The present study was designed to evaluate how COVID-19 restrictions affected colorectal cancer patient care. We would like to mention that in our region, of the three major clinics which treat colorectal cancer, one was completely repurposed for fighting the coronavirus pandemic. Therefore, the patient load usually treated there was redistributed in the remaining two surgical clinics. This can be an explanation why our admission numbers decreased with only 12% in a year.

According to our data we treated more advanced cancers, several of which was emergency. The fact that there was no substantial difference between the duration of hospitalization of these patients in comparison with the pre-pandemic ones, shows our intention to discharge as quickly as possible our patients in order to limit the chance of nosocomial infection (with COVID-19). Yun Xu however reports a longer length of stay of inpatients for palliative and curative resections alike (13).

In our institute an important chunk of the ICU ward and staff was repurposed for treating COVID-19 patients, thus limiting the capacity to a small number of beds where postoperative cancer patients could be admitted. This can be an explanation why we had similar admission rate to the ICU ward, and why patients benefited intensive care for the same amount of time during the pandemic. Because of the bed shortage, a lot of seriously ill patients were treated on the surgical ward.

Pathological Results

From our patient sample almost every variable showed a more advanced cancer in the pandemic group. We would like to point out that in Romania the colorectal cancer screening program is somewhat inexistent, thus limiting the opportunity to diagnose the disease in early stages. The limited number of cases admitted to this study, and fact that there was no screening program in place to be disrupted, could explain why some parameters did not show significant differences. We
believe, that before the COVID-19 restrictions, in comparison to countries with developed medical systems, we already treated more advanced cancers, therefore limiting the extent of the situation to worsen. In international literature, few studies were published that focused on the pathological upstaging of the colorectal cancer in this period with conflicting results. We report significantly more advanced tumor cases (higher stages) in the pandemic if we group our data according to AJCC and the less used DUKES classification. We had more locally advanced cancer (T) in the COVID-19 group. E. Williams et al and M Schinkwin et al found more T2, T3, T4 patients during the pandemic (18,19). Other authors claim that no difference in TNM stages and/or metastatic lymph node yield was found (13,20,21). J.Y.Choi’s data shows significantly more lymph node metastasis and lymphovascular invasion but similar overall TNM staging and perineural invasion in the pandemic (13). A study from Brazil measured the clinical (preoperative) staging distribution of the patients and found similar local invasion and metastasis but more patients with clinically positive lymph nodes, and a higher proportion of clinically advanced cancers in the pandemic (22). We also had significantly more metastases, higher lymph node yield, more vascular and perineural invasion, higher proportion of positive resection margin but similar lymph node ratio and lymphatic invasion in this time. Some authors expect a rise of pathological advanced cancers (colorectal and other) in the following months, years (23-25).

When interpreting the results of this study, the following limitations should be considered. First, the data entered in our archives, at the moment of discharge, relies on several individuals and therefore we cannot exclude inherent bias. Second, this is a single institution’s experience and must be interpreted accordingly. It is unclear yet as to whether these results will be reproducible across other Romanian tertiary clinics.

Conclusion

The COVID-19 pandemic and the measures to contain the spread of the virus had major effects on the colorectal cancer treatment pathways. Fewer diagnosis and surgical interventions were made in this period in Romania and around the world. Delays in treatment could seriously impact the clinical and pathological characteristics of the patients, with possibly worse short and long term outcomes. We do not have enough evidence to exactly quantify the impact of the pandemic, but this study should raise awareness about this particular population of colorectal cancer patients, who should benefit from a very close follow-up. It is important to repeat more similar studies on large samples in order to gain solid evidence. It is quintessential to have precise guidelines in place for future pandemics otherwise colorectal cancer patients could become “collateral damage”.

Conflicts of Interest and Source of Funding

The authors declare no conflict of interest. This work was supported by the University of Medicine, Pharmacy, Science and Technology “Gheorghe Emil Palade” of Târgu Mureș, Research Grant number 294/41 14.01.2020.

Ethics Approval

The present study was approved by the institution’s ethics committee.

References

1. Sanche S, Lin YT, Xu C, Romero-Severson E, Hengartner N, Ke R. High Contagiousness and Rapid Spread of Severe Acute Respiratory Syndrome Coronavirus 2. Emerg Infect Dis. 2020;26(7):1470-1477.
2. Cucinotta D, Vanelli M. WHO Declares COVID-19 a Pandemic. Acta Biomed. 2020;91(1):157-160.
3. Telles CR, Roy A, Ajmal MR, Syed KM, Ahmadd MA, de la Serna JM, et al. Correction: The Impact of COVID-19 Management Policies Tailored to Airborne SARS-CoV-2 Transmission: Policy Analysis. JMIR Public Health Surveill. 2021;7(5):e30007.
4. Mafra da Costa A, Ribeiro AL, Ribeiro AG, Gini A, Cabasaq C, Reis RM, et al. Impact of COVID-19 Pandemic on Cancer-Related Hospitalizations in Brazil. Cancer Control. 2021;28:10732748211038736.
5. Santoro GA, Grossi U, Murad-Regadas S, Nunoo-Mensah JW, Meilgnen A, Di Tanna GL, et al. Delayed colorectal cancer care during COVID-19 pandemic (DECOR-19): Global perspective from an international survey. Surgery. 2021;169(4):796-807.
Fligor SC, Wang S, Allar BG, Tsikis ST, Ore AS, Whitlock AE, et al. Gastrointestinal Malignancies and the COVID-19 Pandemic: Evidence-Based Triage to Surgery. J Gastrointest Surg. 2020;24(10):2357-2373.

Brunner M, Krautz C, Kersting S, Weber GF, Stinner B, Benz SR, et al. Oncological colorectal surgery during the COVID-19 pandemic—a national survey. Int J Colorectal Dis. 2020;35(12):2219-2225.

Maringe C, Spicer J, Morris M, Purushotham A, Nolte E, Sullivan R, et al. The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study Lancet Oncol. 2020;21(8):1023-1034.

COVID-19 pandemic in Romania (Internet) Available from: https://en.wikipedia.org/wiki/COVID-19_pandemic_in_Romania (Accessed 09.09.2021)

Legislation of the SARS-COV-2 pandemic restrictions (Internet) Available from http://legislatie.just.ro/Public/DetailDocument/224706 (Accessed 09.10.2021)

Kutikov A, Weinberg DS, Edelman MJ, Horwitz EM, Uzzo RG, Fisher RI. A War on Two Fronts: Cancer Care in the Time of COVID-19. Ann Intern Med. 2020;172(11):756-758.

Quinn-Scoggins H, Cannings-John R, Moriarty Y, Whitelock V, Whitaker K, Grozeva D, et al. Cancer symptom experience and help-seeking behaviour during the COVID-19 pandemic in the UK: a cross-sectional population survey. BMJ Open. 2021;11(9):e063056.

Choi JY, Park UJ, Lee HG, Cho E, Kim YL, Kim CW, et al. Impact of the COVID-19 Pandemic on Surgical Treatment Patterns for Colorectal Cancer in a Tertiary Medical Facility in Korea. Cancers (Basel). 2021;13(9):2221.

Cui J, Li Z, An Q, Xiao G. Impact of the COVID-19 Pandemic on Elective Surgery for Colorectal Cancer. J Gastrointest Surg. 2021;1-7.

Issaka RB, Taylor P, Baxi A, Iruadoni JM, Ramsey SD, Roth J. Model-Based Estimation of Colorectal Cancer Screening and Outcomes During the COVID-19 Pandemic. JAMA Netw Open. 2021;4(4):e216454.

Abdellatif M, Salama Y, Alhammali T, Eltweri AM. Impact of COVID-19 on colorectal cancer early diagnosis pathway: retrospective cohort study. Br J Surg. 2021;108(4):e146-e147.

COVIDSurg Collaborative. Outcomes from elective colorectal cancer surgery during the SARS-CoV-2 pandemic. Colorectal Dis. 2020;10.1111/cod.15451. Online ahead of print.

Xu Y, Huang ZH, Zheng C, Li C, Zhang YQ, Guo TA, et al. The impact of COVID-19 pandemic on colorectal cancer patients: a single-center retrospective study. BMC Gastroenterol. 2021;21(1):185.

Williams E, Kong JC, Singh P, Prabahakaran S, Warrier SK, Bell S. The impact of the COVID-19 pandemic on colorectal cancer diagnosis and management: A Bional Colorectal Cancer Audit study. ANZ J Surg. 2021;91(10):2091-2096.

Shinkwin M, Silva L, Vogel I, Vogel I, Reeves N, Cornish J, et al. COVID-19 and the emergency presentation of colorectal cancer. Colorectal Dis. 2021;23(8):2014-2019.

Merchant J, Lindsey I, James D, Symons N, Boyce S, Jones O, et al. Maintaining Standards in Colorectal Cancer Surgery During the Global Pandemic: A Cohort Study. World J Surg. 2021;45(3):655-661.

Tschann P, Girotti PNC, Loechner D, Adler S, Feurstein B, Szwierski P, et al. How does the COVID-19 pandemic influence surgical case load and historical outcome for colorectal cancer? A single-centre experience. J Gastrointest Surg. 2021;25(11):2957-2960.

Aguiar S, Riechelmann RP, de Mello CAL, Fratão da Silva JC, Camillo Diogenes ID, Silva Andrade M, et al. Impact of COVID-19 on colorectal cancer presentation. Br J Surg. 2021;108(2):e81-e82.

Hamilton AC, Donnelly DW, Loughrey MB, Turkington RC, Fox C, Fitzpatrick D, et al. Inequalities in the decline and recovery of pathological cancer diagnoses during the first six months of the COVID-19 pandemic: a population-based study. Br J Cancer. 2021;125(6):798-805.

Ricciardello L, Ferrari C, Carnevali M, Gaiannini F, Butitta F, Bazzoli F, et al. Impact of SARS-CoV-2 Pandemic on Colorectal Cancer Screening Delay: Effect on Stage Shift and Increased Mortality. Clin Gastroenterol Hepatol. 2021;19(7):1410-1417.e9.